BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease ...

The company is planning a Phase 2 study for BRTX-100, indicating progress in clinical development and commitment to addressing chronic cervical discogenic pain, which affects a large segment of ...

The pain can range from cervical intervertebral discs, facet joints to atlantoaxial joints. Cervical discogenic pain syndrome is a common source of neck pain with a reported prevalence between 16% to ...